Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT01948297 trial: what clinicians have said so far
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
- NCT01948297 ↗
- Terminated
- Debiopharm International SA
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT01948297 (Debio 1347 in advanced solid tumors with FGFR alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01948297 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Solid Tumours
- Interventions
- Debio1347 (CH5183284)
- Arms
- Part A · Experimental
- Part B · Experimental
- Enrollment
- 77
- Primary outcomes
- Part A: Percentage of Participants With Dose-Limiting Toxicities (DLTs) From Debio 1347
- Part B: Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
- Part B: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
- Part B: Severity of Treatment-Emergent AEs
- Part B: Severity of Laboratory Abnormalities
- Sponsor
- Debiopharm International SA
- Start
- Aug 2013
- Primary completion
- Jun 26, 2020
- Results posted
- No
- Registry record
- NCT01948297 · updated Sep 9, 2020